Corticosteroid Emflaza Receives FDA Approval As Duchenne Muscular Dystrophy Treatment

A new drug approved by the FDA has been shown to delay loss of walking ability for patients diagnosed with Duchenne muscular dystrophy. Emflaza is marketed by Marathon Pharmaceuticals.